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 OPEN ACCESS 
Impacts
• There is limited data on brucellosis patients with 
history of relapse or complications in endemic 
countries of brucellosis.
• Diseases registries like Brucellosis Relapse and 
Complications Registry can be used to perform 
epidemiological studies to identify the main risk 
factors as well as clinical research.
• Registration the occurrence of relapse and 
complication among brucellosis patients provides 
information for better management of patients.
Introduction
Brucellosis is a zoonotic bacterial disease, which 
can cause of significant economic losses due to the 
livestock abortion, and also because of its burden and 
complications in human, especially in developing 
countries, considered as a big concern for public health 
and international trade [1].
True incidence of brucellosis in livestock may be 
10-20  times higher than the reported figures  [2]. 
Brucellosis in humans can cause a wide range of clinical 
manifestations (fever, chillness, myalgia, arthralgia, 
night sweating, fatigue, weight loss, etc) with various 
organ involvements. Brucellosis can present in acute, 
subacute and chronic forms and it causes serious 
complications such as endocarditis or neurobrucellosis. 
The disease has the ability to relapse, and in 5 to 15% 
of cases, even with treatment, relapse is seen. Mortality 
is reported less than 1% of patients with brucellosis 
(Harrison 2019 and Mandell 2020) [2, 3].
Nearly half of the countries with the highest incidence 
rate for human brucellosis including Iran are located in 
the Middle East region [4]. Despite the preventive efforts 
by the health authorities, Iran is still one of the endemic 
countries for the disease. Results of the meta-analysis 
study showed that the highest incidences of brucellosis 
are occurred in west and northwest parts of Iran [5].
Hamadan province is located in the west of Iran. This 
province is known as one of the hubs of animal husbandry 
in the country, so that the production of livestock during 
2016 in Hamadan was 598,000  tons, the province is 
ranked the first in the Western part and 9th throughout the 
country in terms of animal husbandry and livestock [6]. 
Hamadan has always been one of the provinces with 
high incidence of brucellosis in the country  [7] with 
7,318 brucellosis cases from 2009 to 2015 [8].
Despite the introduce and use of standard therapeutic 
options for brucellosis  [9] a proportion of patients 
are encountered with failure in treatment, relapses 
and complications  [10]. Results of a local study in 
Hamadan province declared that the rate of relapse 
among brucellosis patients was 6.45%  [8]. The 
evidence regarding risk factors for relapse are rare. 
Host characteristics like advanced age, immunity status, 
severity of infection, and treatment delays are mentioned 
as the potential risk factors of relapse [8, 10].
Until now no data have been published on the 
epidemiology of relapse and complications of 
brucellosis in Iran with a valid and reliable data. A 
Brucellosis is an endemic bacterial zoonotic disease in develop-
ing countries; that is a serious public health problem in Iran. 
Brucellosis is a life-threatening multi-system disease in human 
with different clinical manifestations, complications and relapse. 
The incidence of brucellosis in Hamadan province, west of Iran is 
high. In addition, there is few reliable and population-based stud-
ies regarding relapse and complications of brucellosis in devel-
oping countries, therefore establishment of the registry system 
in areas with adequate occurrence of cases is needed to better 
understand the predictors of brucellosis relapse and complica-
tions and management of the disease. Detecting occurrence of 
relapse and complications over time and by geographical area 
provide information for further investigations and identification 
of health system deficiencies in the management of patients.
ReseaRch papeR
Establishment of brucellosis relapse  
and complications registry: a study protocol
FARIBA KERAMAT1, MOJGAN MAMANI1, MARYAM ADABI1, SALMAN KHAZAEI2, 
 ZAHRA SHIVAPOOR3, MANOOCHEHR KARAMI4,5
1 Brucellosis Research Center, Hamadan University of Medical Sciences, Hamadan, Iran; 2 Modeling of Noncommunicable Diseases 
Research Center, Hamadan University of Medical Sciences, Hamadan, Iran; 3 Vice-Chancellor for Research and Technology, Hamadan 
University of Medical Sciences, Hamadan, Iran; 4 Social Determinants of Health Research Center, Hamadan University of Medical 
Sciences, Hamadan, Iran; 5 Department of Epidemiology, School of Public Health, Hamadan University of Medical Sciences, 
Hamadan, Iran
Keywords
Brucellosis • Relapse • Complication • Registry • Developing countries
Summary
BRUCELLOSIS RELAPSE AND COMPLICATIONS REGISTRY
E497
published similar study in west of Iran has used data 
from national notification brucellosis surveillance 
system to address baseline characteristics of brucellosis 
patients with potential complications [8]. Therefore, 
robust longitudinal data are needed to better understand 
the predictors of brucellosis relapse and complications 
and management of disease. This study aims to describe 
the protocol of Brucellosis Relapse and Complications 
Registry in Hamadan province, west of Iran 
The objectives of the registry
Identification of the potential risk factors for relapse 
and complications of brucellosis is essential to provide 
a comprehensive understanding of the nature of the 
disease. Considering the limited conducted studies 
regarding brucellosis relapse and complications as 
an endemic country for brucellosis and paucity of 
information, the need to achieve a valid and reliable data 
with considerable sample size is necessary. The registry 
will provide enough motivation for researchers to do 
multiple researches across the fields of medical, nursing 
and public health.
Methodology of the registry
Study design
Brucellosis Relapse and Complications Registry is an 
observational and prospective study enrolling relapse 
and complicated cases of brucellosis. Approval from 
the Ethical Committee of Hamadan University of 
Medical Sciences was obtained (Ref. No. 16.35.1.4218). 
Enrollment and registration of eligible brucellosis 
relapse and complication cases were started from 
September 2015. The recruitment process in primary 
phase was ended in December 2019. All patients must 
provide written informed consent to participate in the 
registry. 
Case definition
A case of brucellosis is define as “a patient with clinical 
manifestations compatible with brucellosis (fever, 
chillness, myalgia, weakness, night sweating, arthralgia) 
and Standard Tube Agglutination Test (STA) ≥ 1:80, 
and 2-mercaptoethanol (2ME) agglutination ≥ 40 or a 
positive blood culture for Brucella” [11]. 
Case classification
• Confirmed case: a clinically compatible illness with 
definitive laboratory evidence of Brucella infection.
• Probable case: a clinically compatible illness with 
at least one of the following: Epidemiologically 
linked to a confirmed human or animal brucellosis 
case or presumptive laboratory evidence, but without 
definitive laboratory evidence, of Brucella infection.
• Suspected case: lab results only without clinical 
information. 
• Relapse: is defined as the recurrence of characteristic 
signs and symptoms (with positive culture or 
serology of brucellosis) occurring at some time after 
the completion of a course of treatment. Patients 
with relapse characteristically have objective 
signs of infection, such as fever, and persistently 
elevated titers of IgG antibodies in their serum. Most 
relapses occur within six months after therapy is 
discontinued, and relapse is not usually due to the 
emergence of antibiotic resistant strains, although 
this has been seen after monotherapy with rifampicin 
or streptomycin [12].
• Complicated case defines as a patient with 
symptoms of brucellosis who has at least one 
involved organ and has a positive serology or culture 
simultaneously.
Eligibility criteria
The new cases of brucellosis without any complications 
as well as non-native patients will be excluded from study.
Data collection procedure 
The data collection procedure obviously showed in 
Figure 1. As shown, identified cases of relapse brucellosis 
or patients with complications related to brucellosis by 
physicians in rural or urban health centers, private clinics 
and hospitals in Hamadan province, using a referral 
form is referred to a trained infectious specialist present 
at Sina Hospital in official hours and Imam Khomeini 
Clinic in other times for final diagnosis and examination 
of documents. 
After confirmation and meets the eligibility criteria by 
focal-point, completed the questionnaire for patients 
and finally data is entered in the software by the trained 
expert. 
Recorded data is refined and reviewed monthly to 
fixing defects and avoid duplication of records. 
Repetitive case will be recorded as a new item in the 
software if they have relapse criteria or complications. 
Patients are actively re-examined every three months 
by mentioned trained infectious specialist and record 
the results. The incomplete questionnaires will be 
followed up by the relevant expert to correct the 
deficiencies. 
Measurement tool
A researcher- developed questionnaire is used to 
collect data. To ensure the validity of questionnaire, it 
was designed by three of researchers. Subsequently, 
the questionnaire is reviewed and validated by a 
multidisciplinary panel of experts including: principal 
investigator, microbiologist, health professional, 
epidemiologist and four infectious disease specialists. 
For comparability of results, we used ICD-10 codes 
for coding of relapse and complications. To ensure 
uniformity in the register by the executive director, a 
dictionary was provided for the questionnaire. 
This questionnaire including: 
1. demographic characteristics (age, sex, pregnancy 
status, residency, place of residency, job); 
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2. information regarding disease (history of disease, 
date of infection, treatment status);
3. risk factors of disease (Contact with domesticated 
animals, history of unpasteurized dairy consumption), 
4. clinical symptoms (e.g. fever, chillness, weakness, 
fatigue, sweating, sleep disorders, weight loss, anorexia, 
headache, generalized body pain, lumbar pain, back 
pain, joint pain, abdominal pain, testicular pain, 
constipation, diarrhea, cough, behavioral disorders);
5. clinical signs (e.g. joint swelling, splenomegaly, 
vertebral tenderness, orchitis, rash, lymphadenopathy, 
hepatomegaly, nuchal rigidity, heart murmur);
6. complications of brucellosis including:
• osteoarticular complications - e.g. sacroiliitis, 
spondylitis, peripheral arthritis, osteomyelitis, 
bursitis, and tenosynovitis,
• gastrointestinal complications - e.g. nausea, 
vomiting, and abdominal discomfort. Rare 
cases of ileitis, colitis and spontaneous bacterial 
peritonitis have been reported,
• hepatobiliary complications - e.g. Hepatic 
abscesses and chronic suppurative lesions, acute 
and chronic cholecystitis,
• respiratory tract complications - e.g. hilar and 
paratracheal lymphadenopathy, interstitial 
pneumonitis, bronchopneumonia, lung nodules, 
pleural effusions, and empyema,
• genitourinary complications - e.g. orchitis and 
epididymitis, pelvic abscesses and salpingitis,
• pregnancy - e.g. brucellosis during the course of 
pregnancy carries the risk of spontaneous abortion 
or intrauterine transmission to the infant, 
• cardiovascular complications - e.g. infective 
endocarditis,
• neurological complications - e.g. neurobrucellosis, 
cerebral vasculitis, mycotic aneurysms, brain and 
epidural abscesses, infarcts, hemorrhage, and 
cerebellar ataxia,
Fig. 1. Flowchart of brucellosis relapse and complications registry.
BRUCELLOSIS RELAPSE AND COMPLICATIONS REGISTRY
E499
• peripheral nerve complications include neuropathy/
radiculopathy, Guillain-Barré syndrome, and a 
poliomyelitis-like syndrom,
• cutaneous complications - e.g. rashes, nodules, 
papules, erythema nodosum, petechiae, and purpura,
• ophthalmic complications - e.g. uveitis. It can 
present as chronic iridocyclitis, nummular 
keratitis, multifocal choroiditis or optic neuritis;
7. para laboratory and imaging findings [Wright, 2ME, 
Coomb’s Wright, Blood culture, Bone marrow 
aspiration culture, ESR (mm/h), CRP (qualitative), 
WBC (mm3) and Hb (g/dl) , Whole body bone scan 




In order to ensure the quality of the data, several steps 
were considered. Table I shows these steps.
Quality control
During the registration process, all completed 
questionnaires will be reviewed by the program manager. 
In the case of a defect, a questionnaire will be sent to 
the relevant physician for correction, and the repeated 
questionnaires will be deleted.
To ensure proper diagnosis, the program manager will 
randomly review some of the referral patients’ questions.
In order to ensure that data entry is adapted to the 
software and the questionnaire, randomly each week, 
a number of patients’ questionnaires registered by the 
registration expert will be reviewed by the executive 
director of the program.
Coverage of registration of eligible cases will be 
estimated using completeness percent. Moreover, 
frequency distribution of registered cases among a 
variety of characteristics includes sex, age groups and 
residency areas will be estimated.
In regard of representativeness of the study population, 
given that the Sina Hospital is referral hospital, and 
because of the presence of infectious specialists in 
Imam Khomeini Clinic simultaneously, it seems that 
the registered patients in this system represent all 
patients with relapse and complications of brucellosis in 
Hamadan province.
Ethical considerations
The study protocol has been approved by Ethics 
Committee of Hamadan University of Medical Sciences 
was obtained (Ref. No: 16.35.1.4218). Entry to the 
study will be voluntary. Prior to registration, about the 
confidentiality of information, planning the registry, 
the purpose of the project, the non-interference of the 
registration process with the treatment process will be 
explained for patients.
Discussion
Registries are powerful instruments to support health 
care and research, and usually made on data collected 
from events or outcomes interested for specialists in 
daily healthcare and cannot be achieved in another 
way [13].
Brucellosis Relapse and Complications Registry 
is the first registry regarding brucellosis relapse 
and complications in Iran. The aim of this registry 
is providing better understanding of the nature 
of the disease and effectiveness of treatments by 
identification of potential risk factors for relapse and 
complications of brucellosis. As we know brucellosis 
a rare disease in advanced countries with eradication 
programs [14]. For example in France, from 2004 to 
2013 according human brucellosis surveillance a total 
of 250  brucellosis cases was notified (0.3  cases per 
million)  [15]. But in Iran, the situation is different, 
so that in Hamadan province (2.4% of the country’s 
population) the number of 7,318 brucellosis cases was 
notified in a seven year period [8]. 
Vast majority of studies in the field of brucellosis in 
developed countries is restricted to case reports or 
case series studies, because the number of patients 
in these countries is not considerable, in other words, 
brucellosis is not the problem of those countries. In 
limited studies conducted in the country [8   16], the 
results are based national modifiable surveillance 
system data, which are not collected for research 
purposes and are based on the passive surveillance. 
The generalizability results of other studies because 
of their low sample size or restricted study area are 
also low [2, 3, 17]. Given the same situation in other 
endemic brucellosis countries, establishment of 
relapse and complications of brucellosis registry is 
essential in endemic areas.
Conclusions
Developing Brucellosis Relapse and Complications 
Registry in endemic countries with adequate occurrence 
of relapse and complications is essential. Outputs of these 
registries can be used to perform epidemiological studies 
to identify the main risk factors as well as clinical research. 
Detecting occurrence of relapse and complication over 
time and by geographical area provide information for 
further investigations and identification of health system 
deficiencies in the management of patients.
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